INmune Bio Inc. Announces USPTO Allowance of Key Patent Covering Its DN-TNFa Platform Technology for Treating Cancer

September 12, 2019 sandiegobiotech News Comments Off on INmune Bio Inc. Announces USPTO Allowance of Key Patent Covering Its DN-TNFa Platform Technology for Treating Cancer

LA JOLLA, Calif., Sept. 12, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that reprogram the patient?s innate immune system to fight disease, announced today that the United States Patent and Trademark Office (USPTO) has given formal notice of allowance to Patent Application Serial No. 15/776,061, titled ?CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NUCROSIS FACTOR?, which covers INmune?s INB03 Program utilizing dominant negative TNF? (DN-TNF?) technology for treating cancer.

Related Articles

No Picture
News

INmune Bio, Inc. Schedules Conference Call to Report 2020 Second Quarter Financial Results

July 31, 2020 sandiegobiotech News, Syndication Comments Off on INmune Bio, Inc. Schedules Conference Call to Report 2020 Second Quarter Financial Results

LA JOLLA, Calif, July 31, 2020 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today… […]

No Picture
News

INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute?s 7th Annual Immuno-Oncology Summit

August 1, 2019 sandiegobiotech News Comments Off on INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute?s 7th Annual Immuno-Oncology Summit

LA JOLLA, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient?s innate immune system to fight disease, today announced that RJ Tesi, M.D., co-found… […]

No Picture
News

INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Over-Allotment Option

July 20, 2020 sandiegobiotech News, Syndication Comments Off on INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Over-Allotment Option

LA JOLLA, Calif., July 20, 2020 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, toda… […]